Skip to main content

Applying high throughput DNA encoded library (DEL) drug screening combined with other advanced technologies in novel ways to deliver small molecule and peptide therapeutics that address some of the most challenging and some previously termed “undruggable” targets in clinical medicine



Targeting Kinases

While there are more than 500 kinases encoded within the human genome with over 70 FDA approved small molecule kinase inhibitors, mostly for cancer indications, resistance to first line inhibitors often leads to cancer recurrence and poor prognosis. The development of new drugs that overcome such cancer resistance is still a critical unmet medical need.  Applying DEL technology in novel ways, we screened a library of 7 billion compounds and identified best-in-class new small molecule chemical entities (“NCE”) with single nM IC50s targeting key tyrosine kinases, including ABL1 and its clinically important mutants, including ABL1-T315I, BTK, JAK1/2/3, TRKA/B/C, ROS1, and AurkA/B/C.

Targeting Nuclear Receptors

Nuclear receptors can bind ligand, leading to a conformational change, homo- or hetero-dimerization, nuclear translocation and DNA binding.  Using DEL technologies to screen a proprietary library of stapled peptides, we have identified high affinity binders of the coactivator binding region of the wild type estrogen receptor, ERα, and its mutant, ERα-Y537S.

Driving Apoptosis of Senescent Cells

DNA damage, oxidative stress or oncogenic mutations can activate nuclear translocation of p53 and p53 interacting proteins (p53IP), helping to tether p53 onto the transcriptional promoter of pro-senescence protein, p21.  We are using DEL technology to screen a proprietary stapled peptide library for peptides that can disrupt Foxo4-p53 interaction, a key driver of shepherding cells towards senescence.

Deliver Graphic


Our early pipeline is focused on identifying novel drug candidates, both small molecules or peptides, that target nuclear receptors, senolytics and tyrosine kinases.



December 14, 2021 in Press Releases

Rapha Capital BioVentures Fund I Launches DELIVER Therapeutics Inc. with $3 Million Convertible Note Financing

DELIVER Therapeutics, Inc. ("DELIVER") a company that plans to apply novel, high-throughput screening technologies combined with chemical innovation to DELIVER therapeutics that address the most difficult problems in clinical medicine has been launched with an initial $3M Convertible…
Read More
November 15, 2021 in News

New use of screening technology finds SARS-CoV-2 treatment target in lab setting

Finding effective treatments for SARS-CoV-2, the viral agent responsible for COVID-19, has been difficult but researchers at Baylor College of Medicine are working to find a potential solution. Much attention…
Read More